Autopsy report · NCT03502746

Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma

“IRB Study Closure”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 5 years 4 months before it stopped.
• 34 participants enrolled.
• Results were posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Arkadiusz Z. Dudek, MD

Sponsor type

University, hospital or other

Conditions

Mesothelioma, Malignant

Interventions

Nivolumab; Ramucirumab

Participants

34

Sites

4

Countries

United States

Trials that died the same way

• Physical Exercise And Cognitive Engagement Outcomes for Mild Neurocognitive Disorder
  “IRB Closure” (81% match in meaning)
• A Pilot Study of mDOT for Immunosuppressant Adherence in Adult Liver Transplant Recipients
  “Merged IRB study created” (75% match in meaning)
• Methadone as an Alternative Treatment for Children Underdoing HSCT
  “Study is closed with the IRB due to no funding. May resume once funding is obtained.” (74% match in meaning)
• A Quality of Life Study Using Insulin Potentiation Targeted LowDose (IPTLD) Chemotherapy and Nutrition Therapy in the Treatment of Cancer
  “The IRB which was overseeing the study stopped overseeing it” (73% match in meaning)
• ACB + IPACK Block With or Without Local Infiltration in RA-TKA
  “The P.I. decided to cancel this study. On 10/08/19, a study closure request was submitted to the IRB.” (73% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.